T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.93
    -1.79 (-3.21%)

    Market Cap: $8.31B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    30%(12/40)
    Avg Surprise
    -3.33%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.33
    Range$0.19 - $0.61
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$0.43+31.7%
    60d ago$0.43+31.0%
    30d ago$0.43+29.8%
    7d ago$0.43+32.5%
    Current$0.33
    Revenue Consensus
    $247M
    Range$243M - $255M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.34 - $0.28
    4 analysts
    Revenue Consensus
    $282M
    Range$272M - $305M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$0.33---
    Jun 26
    Reported Aug 3
    		$0.05N/A-87.80%Miss-70.6%
    Mar 26
    Reported May 6
    		$0.18$0.28-35.71%Miss+500.0%
    Dec 25
    Reported Feb 26
    		$0.14N/A-60.00%Miss-6.7%
    Sep 25
    Reported Nov 3
    		$0.16$0.22-27.27%Miss+700.0%
    Jun 25
    Reported Aug 4
    		$0.17$0.29-41.38%Miss+325.0%
    Mar 25
    Reported May 5
    		$0.03N/A-82.35%Miss+142.9%
    Dec 24
    Reported Mar 3
    		$0.15$0.09+66.67%Beat+250.0%
    Sep 24
    Reported Nov 4
    		$0.02$0.03-33.33%Miss-97.3%
    Jun 24
    Reported Aug 6
    		$0.04$-0.04+200.00%Beat+111.8%
    Mar 24
    Reported May 1
    		$-0.07$-0.04-75.00%Miss+75.0%
    Dec 23
    Reported Feb 28
    		$-0.10$-0.10+0.00%Beat+74.4%
    Sep 23
    Reported Nov 1
    		$0.73$0.10+630.00%Beat+380.8%
    Jun 23
    Reported Aug 1
    		$-0.34$-0.25-36.00%Miss-13.3%
    Mar 23
    Reported May 1
    		$-0.28$-0.34+17.65%Beat+45.1%
    Dec 22
    Reported Feb 28
    		$-0.39$-0.26-50.00%Miss+44.3%
    Sep 22
    Reported Nov 10
    		$-0.26$-0.38+31.58%Beat+60.0%
    Jun 22
    Reported Aug 8
    		$-0.30$-0.57+47.37%Beat+49.2%
    Mar 22
    Reported May 10
    		$-0.51$-0.59+13.56%Beat+26.1%
    Dec 21
    Reported Mar 1
    		$-0.70$-0.68-2.94%Miss+2.8%
    Sep 21
    Reported Nov 4
    		$-0.65$-0.57-14.04%Miss+11.0%
    Jun 21
    Reported Aug 2
    		$-0.59$-0.50-18.00%Miss-25.5%
    Mar 21
    Reported May 10
    		$-0.69$-0.49-40.82%Miss-43.7%
    Dec 20
    Reported Mar 2
    		$-0.72$-0.61-18.03%Miss-63.6%
    Sep 20
    Reported Nov 9
    		$-0.73$-0.44-65.91%Miss-5.8%
    Jun 20
    Reported Aug 10
    		$-0.47$-0.33-42.42%Miss-11.9%
    Mar 20
    Reported May 11
    		$-0.48$-0.37-29.73%Miss-11.6%
    Dec 19
    Reported Mar 3
    		$-0.44$-0.46+4.35%Beat+36.2%
    Sep 19
    Reported Nov 12
    		$-0.69$-0.35-97.14%Miss-60.5%
    Jun 19
    Reported Aug 9
    		$-0.42$-0.42+0.00%Beat+28.8%
    Mar 19
    Reported May 10
    		$-0.43$-0.44+2.27%Beat+27.1%
    Dec 18
    Reported Mar 1
    		$-0.69$-0.44-56.82%Miss-50.0%
    Sep 18
    Reported Nov 9
    		$-0.43$-0.50+14.00%Beat+10.4%
    Jun 18
    Reported Aug 7
    		$-0.59$-0.50-18.00%Miss-31.1%
    Mar 18
    Reported May 8
    		$-0.59$-0.42-40.48%Miss-13.5%
    Dec 17
    Reported Mar 8
    		$-0.46$-0.44-4.55%Miss+4.2%
    Sep 17
    Reported Nov 8
    		$-0.48$-0.40-20.00%Miss+4.0%
    Jun 17
    Reported Aug 9
    		$-0.45$-0.38-18.42%Miss-
    Mar 17
    Reported May 5
    		$-0.52$-0.36-44.44%Miss-
    Dec 16
    Reported Mar 10
    		$-0.48$-0.36-33.33%Miss-
    Sep 16
    Reported Nov 7
    		$-0.50$-0.30-66.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio101.75EV/EBITDA62.64x
    Price/FCF439.79xFCF Yield0.23%
    Profitability
    Profit Margin55.20%Operating Margin9.02%
    ROE100.30%ROIC10.99%
    Financial Health
    Debt/Equity1.23xInterest Coverage3.18x
    Current Ratio4.27xQuick Ratio3.72x
    Trading Statistics
    Beta1.67Avg Volume2.25M
    52-Week High$59.3052-Week Low$26.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$53.22
    SMA 20$51.08
    SMA 50$53.37
    SMA 200$38.39
    EMA 10$53.54
    EMA 20$52.67
    EMA 50$51.07
    EMA 200$42.05

    MACD

    Line: 0.81Signal: 0.21Hist: 0.61

    ADX

    ADX: 23.6+DI: 24.4-DI: 15.6

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down28.0
    PSAR$51.54

    Bollinger Bands

    Upper Band$56.90
    Lower Band$45.25
    %B Position2281%(Upper)
    Band Width0.74

    RSI (14-Day)

    Neutral
    54.8

    Momentum Oscillators

    Stoch %K71.7
    Stoch %D76.1
    Williams %R-37.3
    ROC (10d)10.6%
    Momentum5.19
    CCI (20d)93.9
    MFI (14d)70.1

    Volatility Measures

    ATR (14d)$2.45(4.5%)
    StdDev (20d)2.91
    Hist Vol60.4%(High)

    Volume Flow

    VWAP$54.43
    OBV43.3M
    AD Line13.1M
    CMF (20d)-0.055

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.5x(Low)
    VWMA (20d)$50.71

    Pivot Points

    R3$58.23
    R2$57.10
    R1$56.41
    Pivot Point$55.28
    S1$54.59
    S2$53.46
    S3$52.77

    Advanced Oscillators

    TSI9.04
    Ultimate Osc50.8
    KST-16.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$240.34M$204.92M$192.57M$161.71M$141.15M$120.86M$108.19M$83.88M$73.47M$63.47M$43.97M$165.81M
    Cost of Revenue$41.19M$33.51M$38.14M$28.09M$18.94M$15.54M$15.40M$9.34M$8.30M$5.44M$9.77M$3.51M
    Gross Profit$199.14M$171.41M$154.43M$133.62M$122.21M$105.31M$92.78M$74.54M$65.16M$58.03M$34.20M$162.31M
    Operating Expenses$177.47M$136.61M$103.94M$104.25M$87.37M$96.69M$62.84M$62.10M$56.35M$67.30M$46.69M$47.52M
    R&D$95.34M$48.40M$41.19M$40.88M$31.78M$46.36M$23.88M$20.14M$17.56M$32.72M$17.45M$14.75M
    SG&A$82.13M$88.22M$62.74M$63.37M$55.59M$50.33M$38.96M$41.97M$38.79M$34.58M$31.15M$32.77M
    Operating Income$21.67M$34.80M$50.49M$29.36M$34.84M$8.62M$29.95M$12.43M$8.82M$-9,270,000$-12,485,000$114.78M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$16.57M$16.82M$6.53M$6.72M$6.72M$6.76M$6.93M$10.83M$3.98M$2.29M$2.43M$3.71M
    Income Before Tax$10.23M$20.36M$45.09M$25.91M$30.92M$5.47M$25.45M$4.27M$6.55M$-10,678,000$-14,026,000$113.93M
    Income Tax Expense$2.45M$586,000$22.06M$-364,986,000$2.73M$408,000$2.12M$388,000$-328,000$29,000$390,000$0
    Net Income$7.78M$19.78M$23.04M$390.89M$28.19M$5.06M$23.33M$3.88M$6.88M$-10,707,000$-14,416,000$113.93M
    EBITDA$26.89M$37.18M$51.61M$32.21M$36.72M$11.25M$31.05M$13.76M$9.44M$-9,339,000$-12,397,000$118.19M
    EBIT$26.81M$37.18M$51.63M$32.63M$37.64M$12.22M$32.38M$15.10M$10.53M$-8,390,000$-11,595,000$117.64M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TGTX

    News

    TG Therapeutics (TGTX) Tests A Key Moving Average, Is The Stock Fully Priced?

    TG Therapeutics (TGTX) stock has formed a cup-style base after an early August sell-off and is now testing a key moving average. While the company has shown strong recent returns, analysts have a consensus price target of $51.71, suggesting the stock is currently slightly overvalued at its last close of $56.01, or fairly priced at its current price of $53.22. However, when viewed through a P/E lens, the stock's 18x earnings is slightly above the US Biotechs average but below an estimated fair ratio of 25.7x, indicating mixed signals for investors.

    Simply Wall Street•8/25/26•
    Somewhat-Bearish

    TG Therapeutics (TGTX) Stock Still Looks Cheap Even After Strong Returns

    TG Therapeutics (TGTX) has seen significant returns over the past three years, yet its stock appears undervalued based on current valuation checks. The company trades at a lower P/E ratio compared to its industry and peers, and its tailored fair P/E also suggests it's priced under its benchmark. The key to future valuation lies in its ability to convert its pipeline into sustainable earnings, with differing community views on its flagship product BRIUMVI.

    Sahm•8/23/26•
    Somewhat-Bullish

    TGTX Jumps As TG Therapeutics Hikes 2026 Revenue Outlook

    TG Therapeutics Inc. (TGTX) shares jumped 9.62% after the company increased its 2026 revenue guidance to approximately $950 million, driven by strong U.S. BRIUMVI sales for multiple sclerosis treatment. While Q2 2026 EPS missed estimates, revenue growth was robust at 70% year-over-year, and analysts have raised price targets, reflecting bullish sentiment despite some event-driven volatility and takeover rumors. The company's strong commercialization of BRIUMVI, high gross margins, and positive pipeline data underpin its growth trajectory.

    StocksToTrade•8/22/26•
    Bullish

    TG Therapeutics (TGTX) Stock Still Looks Cheap Even After Strong Returns

    TG Therapeutics (TGTX) has shown impressive returns of 388.0% over three years, yet its stock appears undervalued based on various valuation checks. The company's P/E ratio of 16.2x is below both the biotech industry average and its peer group, suggesting it's priced lower than its implied fair value. While there's a strong bull case around its drug BRIUMVI, risks include reliance on this single revenue source and potential competitive threats.

    Simply Wall Street•8/21/26•
    Bullish

    TGTX Stock Whipsaws As BRIUMVI Growth Fuels Bold 2026 Outlook

    TG Therapeutics (TGTX) stock saw an 11.61% increase after upbeat trial results and raised 2026 revenue guidance to approximately $950 million, primarily driven by strong BRIUMVI sales. Despite a mixed Q2 2026 earnings report with an EPS miss, the company's strong top-line growth, $612 million in cash, and pipeline expansion into new indications like myasthenia gravis and schizophrenia are fueling investor confidence. Wall Street analysts have also increased price targets for TGTX, reflecting a belief in its long-term growth story.

    StocksToTrade•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About TGTX

    Does TGTX pay dividends?
    TG Therapeutics Inc (TGTX) does not currently pay a regular dividend.
    What is TGTX's P/E ratio?
    TG Therapeutics Inc has a price-to-earnings (P/E) ratio of 101.75.
    What is TGTX's market cap?
    TG Therapeutics Inc (TGTX) has a market capitalization of $8.31B with a current stock price of $53.93.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In